Posted by Michael Wonder on 02 Nov 2021
EMA ends rolling review of the antibodies bamlanivimab and etesevimab for COVID-19 following withdrawal by Lilly
2 November 2021 - EMA has ended the rolling review of bamlanivimab and etesevimab, two antibodies for the treatment of COVID-19 developed by Elli Lilly Netherlands , after the company informed the Agency that it was withdrawing from the process.
Since March 2021, EMA’s CHMP has been reviewing data on these medicines as part of a rolling review.
